17 completed. 17 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 17 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Comparator: new trials by email Literature Review of Comparator trials Research Report on Comparator
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Safety and Efficacy of MoodElite T-4003-1 on Improving Mood in a Healthy Adult Population With Mild to Moderate Depressive Symptoms Not Eligible for Therapeutic Intervention MoodElite T-4003-1, Comparator, Placebo - Mood | Phase 1 / Phase 2 | Completed | Chenland Nutritionals Inc. | 44 | 2022-03-24 | 2023-03-22 |
| Investigation of the Efficacy and Safety of Three Test Products and Comparator on Muscular Performance After the Initiation of a Resistance Training Program Test Product 1, Test Product 2, Test Product 3 - Muscle Strength | Phase 2 | Completed | Roquette Canada, LTD. | 100 | 2021-04-01 | 2022-04-27 |
| Nitric Oxide Releasing Sinus Irrigation (NOSi) to Treat Recalcitrant Chronic Rhinosinusitis (RCRS) Nitric Oxide, Budesonide - Chronic Sinusitis | Phase 2 | Completed | Sanotize Research and Development corp. | 56 | 2019-10-27 | 2022-06-30 |
| AMZ001 for the Treatment of Knee Osteoarthritis Symptoms AMZ001, Placebo, Comparator - Osteoarthritis, Knee | Phase 2 / Phase 3 | Completed | Amzell | 444 | 2018-10-04 | 2020-10-06 |
| Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease AMX0035, Placebo - Alzheimer Disease | Phase 2 | Completed | Amylyx Pharmaceuticals Inc. | 95 | 2018-09-14 | 2025-03-07 |
| The Clinical Trial to Evaluate the Efficacy and Safety of CKD-497 CKD-497 200mg, CKD-497 300mg, CKD-497 placebo - Respiratory Infection | Phase 2 | Completed | Chong Kun Dang Pharmaceutical | 220 | 2018-05-29 | 2020-02-06 |
| Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis Dalbavancin, Comparator - Osteomyelitis | Phase 2 | Completed | Durata Therapeutics Inc., an affiliate of Allergan plc | 80 | 2016-03-15 | 2019-01-04 |
| Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia SM-1, Comparator, Placebo - Short-term Insomnia | Phase 2 | Completed | Sequential Medicine Ltd | 39 | 2016-02-01 | 2018-03-06 |
| Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss AUT00063, Placebo - Age-Related Hearing Loss | Phase 2 | Completed | Autifony Therapeutics Limited | 78 | 2015-01-01 | 2018-08-09 |
| Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo AUT00063, Placebo - Tinnitus, Subjective | Phase 2 | Completed | Autifony Therapeutics Limited | 91 | 2014-10-01 | 2016-03-31 |
| Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate Glycopyrrolate, Comparator - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | Chiesi Farmaceutici S.p.A. | 281 | 2012-03-01 | 2021-10-29 |
| Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis Placebo, rBet v1-FV - Allergic Rhinoconjunctivitis | Phase 2 | Completed | Allergopharma GmbH & Co. KG | 37 | 2010-10-01 | 2014-01-24 |
| Study on DMMET-01 Versus Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetes Patients DMMET-01, Metformin Hydrochloride - Diabetes Type 2 | Phase 2 / Phase 3 | Completed | Laboratorios Silanes S.A. de C.V. | 20 | 2009-03-01 | 2010-05-18 |
| Milrinone Inhaled in Cardiac Surgery Milrinone, Normal saline - Valvular Stenosis, Valvular Insufficiency | Phase 2 | Completed | Andre Denault | 124 | 2009-02-01 | 2013-10-25 |
| Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative Placebo, rBet v1-FV - Allergic Rhinoconjunctivitis | Phase 2 | Completed | Allergopharma GmbH & Co. KG | 14 | 2007-12-01 | 2013-11-08 |
| Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia NXL103, comparator - Community Acquired Pneumonia | Phase 2 | Completed | Novexel Inc | 302 | 2007-10-01 | 2009-01-09 |
| Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens placebo, rPhleum - Type I-Allergy | Phase 2 | Completed | Allergopharma GmbH & Co. KG | 50 | 2007-09-01 | 2013-11-08 |
Alzheimer Disease (1) · Bronchitis (1) · Community-Acquired Pneumonia (1) · Coronary Artery Disease (1) · Diabetes Mellitus, Type 2 (1) · Hearing Loss (1) · Hypertension, Pulmonary (1) · Osteoarthritis, Knee (1) · Osteomyelitis (1) · Parasomnias (1) · Presbycusis (1) · Pulmonary Disease, Chronic Obstructive (1) · Respiratory Tract Infections (1) · Sinusitis (1) · Tinnitus (1)
Allergopharma GmbH & Co. KG (3) · Autifony Therapeutics Limited (2) · Amylyx Pharmaceuticals Inc. (1) · Amzell (1) · Andre Denault (1) · Chenland Nutritionals Inc. (1) · Chiesi Farmaceutici S.p.A. (1) · Chong Kun Dang Pharmaceutical (1) · Durata Therapeutics Inc., an affiliate of Allergan plc (1) · Laboratorios Silanes S.A. de C.V. (1) · Novexel Inc (1) · Roquette Canada, LTD. (1) · Sanotize Research and Development corp. (1) · Sequential Medicine Ltd (1)
Canada (4) · Germany (3) · United States (3) · Ukraine (2) · United Kingdom (2) · Chile (1) · Croatia (1) · Czechia (1) · Denmark (1) · Estonia (1) · Mexico (1) · Peru (1) · Poland (1) · Romania (1) · South Africa (1)
David Crowley, MD (2) · Amin Javer, MD (1) · Dave Singh, MD (1) · Deepen Patel, MD, CCFP (1) · Jaydip Ray, MD (1) · Maha Ahamad, MD (1) · Patrick Yeramian, MD (1) · Robert Frisina, PhD (1) · Sabina Rak, Prof.Dr.med. (1) · Thomas Dahl, PhD (1)
PMID 23621350, PMID 27109816, PMID 27470232, PMID 30648126, PMID 30939361, PMID 31837050, PMID 37941072, PMID 39131742
2008 (1)